Paper Details

  1. Home
  2. Paper Details

Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.

Author: BarnesG L, CarmanD, ChaissonR E, DawsonR, DormanS E, EfronA, GupteN, HoffmanJ, McIlleronH, NarunskyK, WhitelawA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Daily rifapentine (RPT) at 450 mg or 600 mg was safe and well-tolerated in adults with sputum smear-positive pulmonary tuberculosis. Both regimens showed a trend towards greater efficacy compared to rifampicin, with a higher rate of sputum culture conversion at 8 weeks.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Rifapentine (RPT) has potent activity against Mycobacterium tuberculosis; however, the optimal dose for anti-tuberculosis treatment is unknown. OBJECTIVE: To determine the antimicrobial activity, safety and tolerability of RPT 450 mg or 600 mg administered daily during the first 8 weeks...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26056101

データ提供：米国国立医学図書館（NLM）

Rifapentine: A New Frontier in Tuberculosis Treatment

Tuberculosis (TB) is a serious infectious disease that continues to pose a significant global health threat. Researchers in the field of infectious disease are constantly working to develop new and effective treatments for TB, aiming to improve patient outcomes and minimize the spread of this disease. This study investigates the effectiveness and safety of rifapentine (RPT), a potent antibiotic against Mycobacterium tuberculosis, in treating pulmonary TB.

Rifapentine's Potential for TB Treatment

This study demonstrates the potent activity of RPT against Mycobacterium tuberculosis, exploring the effectiveness of two different daily doses of RPT during the intensive phase of TB treatment. The study found that both RPT regimens were effective in achieving sputum culture conversion, indicating successful bacterial clearance. The study also found that both RPT regimens were safe and well-tolerated, with a similar incidence of adverse events compared to the standard treatment with rifampicin (RMP). This research provides evidence for the potential of RPT as a promising new treatment option for pulmonary TB, offering a potential alternative to RMP.

Implications for TB Treatment

These findings have important implications for TB treatment, highlighting the potential of RPT as a safe and effective alternative to RMP. This study underscores the need for further research to determine the optimal dose of RPT and its long-term efficacy in larger clinical trials. This research provides valuable insights into the potential of RPT as a powerful weapon in the fight against TB, offering hope for improved patient outcomes and better control of this global health threat.

Dr.Camel's Conclusion

This research is like a camel caravan traversing a vast desert landscape, carrying with it the promise of a new and effective treatment for tuberculosis. The findings suggest that RPT holds great potential as a powerful tool in the fight against this ancient disease, offering hope for a brighter future for patients.

Date :
  1. Date Completed 2016-03-25
  2. Date Revised 2019-10-23
Further Info :

Pubmed ID

26056101

DOI: Digital Object Identifier

NIHMS787029

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.